A Phase 2 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 9 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-17.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 149th largest by enrollment of the 224 interventional ones that give a count, is one of 14 that started in 2005, is one of 133 in phase 2, and was the 95th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Gilead Sciences · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Oncolytics Biotech · Sites in United States
Ages 18+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 150 · Phase 3 48 · Phase 4 8
First in 2000; this study’s year is marked. 14 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 224 interventional studies. Of the 144 that completed or were terminated, 50 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 230 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 59th largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2005, is one of 32 in phase 2, and was the 46th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
14 of the studies testing bevacizumab in Colorectal Neoplasms that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06280495Phase 3Sun Yat-sen UniversityNeoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | 2026-12-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT07007728Peking University Cancer Hospital & InstituteIparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | 2026-12-31 |
| NCT03401294University of SaskatchewanConversion From Unresectable To Resectable Metastatic Colorectal Cancer. | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with locally advanced primary rectal cancer. Patients will receive 4 courses of Avastin at a dose of 5 mg/kg intravenously (iv) every 2 weeks and for 38 days Xeloda at dose of 825 mg/kg twice daily orally, plus radiation therapy. After surgery, adjuvant treatment with 5-fluorouracil/leucovorin and, at the discretion of the investigator, with Avastin 5 mg/kg iv every 2 weeks for at least 6 months will be given.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda] · Radiation: Radiation therapy · Procedure: Mesorectal excision · Drug: 5-fluorouracil · Drug: leucovorin
5 mg/kg intravenously every 2 weeks, 4 cycles
825 mg/m2 twice daily orally, 38 days
Total dose of 45 Gy over 38 days
6-8 weeks after completion of neoadjuvant treatment
Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
Percentage of Participants With Pathological Complete Response (pCR)
pCR was defined as the absence of viable tumor cells, as determined by standard histologic procedure, in the tumor specimen (including regional lymph nodes) obtained at surgery. In order to minimize evaluation bias, tumor specimens were analyzed by both a central and local pathologist. The number of participants with pathological tumor stage 0 (pT0) and regional lymph nodes stage 0 (pN0) at surgery was determined. pCR was defined as the number of participants with pT0 and pN0 at surgery divided by the total number of participants with pathological tumor stage data collected.
Time frame: 6 to 8 weeks following completion of neoadjuvant treatment
Percentage of Participants by Primary Tumor (T), Regional Lymph Nodes (N), and Distant Metastasis (M) Clinical Stage at Baseline and at the End of Neo-Adjuvant Treatment (NAT)
The frequencies of clinical tumor stage T (0, 1, 2, 3, 4, or X), regional lymph nodes stage N (0, 1, 2, 3, or 4), and distant metastasis clinical stage M (0, 1, or X) at baseline and at the end of NAT were assessed. The frequencies of pathological tumor stage T and regional lymph nodes stage N at surgery were evaluated. The clinical tumor and lymph node status was assessed by clinical examination, endosonography, and/or rectosigmoidoscopy, and pelvic and abdomen computerized tomography (CT) scan or magnetic resonance imaging (MRI). Response to treatment had to be assessed within 6 weeks after end of treatment by using the same techniques performed at baseline.
Time frame: Baseline (BL) and end of neoadjuvant treatment (within 6 weeks after the completion of study treatment)
Percentage of Participants Undergoing Sphincter-Saving Surgery by Type of Procedure
Time frame: 6 to 8 weeks after completion of study treatment
Percentage of Participants With Complete Response (CR) at the End of Neoadjuvant Treatment
Percentage of participants with CR was evaluated as the proportion of participants with complete response for the target and non-target lesions, separately, at the end of NAT according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions or all non-target lesions and normalization of tumor marker levels.
Time frame: BL and within 6 weeks after the completion of study treatment
Percentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment
Percentage of participants with an overall response of CR was evaluated as the proportion of participants with CR for the target and non-target lesions plus absence of new lesions at the end of NAT according to RECIST. CR was defined as disappearance of all target lesions, all non-target lesions, and normalization of tumor marker levels.
Time frame: BL and within 6 weeks after the completion of study treatment
Percentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment
The percentage of participants with new lesions located at the primary tumor site were evaluated at the end of NAT.
Time frame: BL and within 6 weeks after the completion of study treatment
Percentage of Participants With Relapse During Follow-Up
The percentage of participants with local and/or regional relapse during follow-up. New lesions located at rectum or at colon or at lymph node detected at the end of NAT were evaluated as local and/or regional relapse.
Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months
Disease-Free Survival (DFS) - Percentage of Participants With an Event
DFS was defined as the time from treatment start date to the date of first progression of disease or date of death due to any cause.
Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months
DFS - Time to Event
The time in months from date of start-of-treatment to the date of event defined as the first documented disease progression or death due to any cause. If a participant did not have an event, the time was censored at the date of last adequate tumor assessment. DFS was estimated using the Kaplan-Meier method.
Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months
Overall Survival (OS) - Percentage of Participants With an Event
OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive.
Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months
OS - Time to Event
OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive. OS was estimated using the Kaplan-Meier method.
Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months
Time to Disease Progression (TTP) - Percentage of Participants With an Event
TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer.
Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months
TTP - Time to Event
TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer. TTP was estimated using the Kaplan-Meier method.
Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months
| Milestone | Bevacizumab (Bv)+Capecitabine/Bv+Leucovorin+5-fluorouracil |
|---|---|
| Started | 43 |
| Completed | 19 |
| Not completed | 24 |
| Withdrew: Adverse event | 10 |
| Withdrew: Progression of disease | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Patient non-compliance | 3 |
| Withdrew: Medical decision | 6 |
| Withdrew: Death | 1 |
pCR was defined as the absence of viable tumor cells, as determined by standard histologic procedure, in the tumor specimen (including regional lymph nodes) obtained at surgery. In order to minimize evaluation bias, tumor specimens were analyzed by both a central and local pathologist. The number of participants with pathological tumor stage 0 (pT0) and regional lymph nodes stage 0 (pN0) at surgery was determined. pCR was defined as the number of participants with pT0 and pN0 at surgery divided by the total number of participants with pathological tumor stage data collected.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Percentage of Participants With Pathological Complete Response (pCR) | 10.00 (2.79 to 23.66) |
The frequencies of clinical tumor stage T (0, 1, 2, 3, 4, or X), regional lymph nodes stage N (0, 1, 2, 3, or 4), and distant metastasis clinical stage M (0, 1, or X) at baseline and at the end of NAT were assessed. The frequencies of pathological tumor stage T and regional lymph nodes stage N at surgery were evaluated. The clinical tumor and lymph node status was assessed by clinical examination, endosonography, and/or rectosigmoidoscopy, and pelvic and abdomen computerized tomography (CT) scan or magnetic resonance imaging (MRI). Response to treatment had to be assessed within 6 weeks after end of treatment by using the same techniques performed at baseline.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Baseline: T0, N0 | 0 |
| End of NAT: T0, N0 | 4.65 |
| Baseline: T1, N0 | 0 |
| End of NAT: T1, N0 | 4.65 |
| Baseline: T1, NX | 0 |
| End of NAT: T1, NX | 2.33 |
| Baseline: T2, N0 | 0 |
| End of NAT: T2, N0 | 18.60 |
| Baseline: T2, N1 | 9.30 |
| End of NAT: T2, N1 | 9.30 |
| Baseline: T2, NX | 0 |
| End of NAT: T2, NX | 6.98 |
| Baseline: T3, N0 | 32.56 |
| End of NAT: T3, N0 | 18.60 |
| Baseline: T3, N1 | 46.51 |
| End of NAT: T3, N1 | 9.30 |
| Baseline: T3, N2 | 0 |
| End of NAT: T3, N2 | 2.33 |
| Baseline: T3, NX | 2.33 |
| End of NAT: T3, NX | 6.98 |
| Baseline: T4, N0 | 0 |
| End of NAT: T4, N0 | 4.65 |
| Baseline: T4, N1 | 2.33 |
| End of NAT: T4, N1 | 0 |
| Baseline: T4, N2 | 2.33 |
| End of NAT: T4, N2 | 0 |
| Baseline: T4, N3 | 2.33 |
| End of NAT: T4, N3 | 0 |
| Baseline: TX, N0 | 0 |
| End of NAT: TX, N0 | 2.33 |
| Baseline: TX, N2 | 2.33 |
| End of NAT: TX, N2 | 0 |
| Baseline: M0 | 97.67 |
| End of NAT: M0 | 81.40 |
| Baseline: M1 | 2.33 |
| End of NAT: M1 | 2.33 |
| Baseline: MX | 0 |
| End of NAT: MX | 9.30 |
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Anterior resection | 70.0 |
| Abdomen-peritoneal amputation (Miles) | 22.5 |
| Other | 3.0 |
| Colostomy, temporary (n=32) | 47.50 |
| Colostomy, definitive (n=32) | 32.50 |
| No colostomy | 20.0 |
Percentage of participants with CR was evaluated as the proportion of participants with complete response for the target and non-target lesions, separately, at the end of NAT according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions or all non-target lesions and normalization of tumor marker levels.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| CR of target lesion(s) | 11.63 |
| CR of non-target lesion(s) | 18.60 |
Percentage of participants with an overall response of CR was evaluated as the proportion of participants with CR for the target and non-target lesions plus absence of new lesions at the end of NAT according to RECIST. CR was defined as disappearance of all target lesions, all non-target lesions, and normalization of tumor marker levels.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Percentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment | 9.30 |
The percentage of participants with new lesions located at the primary tumor site were evaluated at the end of NAT.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Percentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment | 4.65 |
The percentage of participants with local and/or regional relapse during follow-up. New lesions located at rectum or at colon or at lymph node detected at the end of NAT were evaluated as local and/or regional relapse.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| No Relapse | 84.21 |
| 1 Relapse | 7.89 |
| 2 Relapses | 7.89 |
DFS was defined as the time from treatment start date to the date of first progression of disease or date of death due to any cause.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Disease-Free Survival (DFS) - Percentage of Participants With an Event | 30.23 |
The time in months from date of start-of-treatment to the date of event defined as the first documented disease progression or death due to any cause. If a participant did not have an event, the time was censored at the date of last adequate tumor assessment. DFS was estimated using the Kaplan-Meier method.
| months | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| DFS - Time to Event | 27.43 ± 1.71 |
OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Overall Survival (OS) - Percentage of Participants With an Event | 25.58 |
OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive. OS was estimated using the Kaplan-Meier method.
| months | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| OS - Time to Event | 32.14 ± 1.46 |
TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer.
| percentage of participants | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Time to Disease Progression (TTP) - Percentage of Participants With an Event | 27.91 |
TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer. TTP was estimated using the Kaplan-Meier method.
| months | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| TTP - Time to Event | 27.68 ± 1.72 |
Collected over Adverse events were collected from the date of first study-drug administration until 28 days after the last dose of study drug administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bv+Capecitabine/Bv+Leucovorin+5-FU | — | 8/42 (19%) | 39/42 (92.9%) |
| Event | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| DiarrhoeaGastrointestinal disorders | 1/42 |
| Miocardic ischemiaCardiac disorders | 1/42 |
| Bowel perforationGastrointestinal disorders | 1/42 |
| Cardiac ischemiaCardiac disorders | 1/42 |
| Anastomosis dehiscenceInjury, poisoning and procedural complications | 1/42 |
| Intestinal occlusionGastrointestinal disorders | 1/42 |
| Postoperative abscessInjury, poisoning and procedural complications | 1/42 |
| IpokaliemiaMetabolism and nutrition disorders | 1/42 |
| Event | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| DiarrheaGastrointestinal disorders | 18/42 |
| ProctalgiaGastrointestinal disorders | 10/42 |
| NauseaGastrointestinal disorders | 9/42 |
| HematocheziaGastrointestinal disorders | 8/42 |
| LeukopeniaBlood and lymphatic system disorders | 7/42 |
| Rectal tenesmusGastrointestinal disorders | 7/42 |
| NeutropeniaBlood and lymphatic system disorders | 6/42 |
| Abdominal painGastrointestinal disorders | 6/42 |
| AstheniaGeneral disorders | 6/42 |
| HypertensionVascular disorders | 6/42 |
Intent to treat (ITT) population: all participants who were included in the trial by signing the informed consent and were assigned to a study patient number.
| Age, Continuous(years) | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Mean | 61.49 ± 10.85 |
| Sex: Female, Male(Participants) | Bv+Capecitabine/Bv+Leucovorin+5-FU |
|---|---|
| Female | 18 |
| Male | 25 |
The record gives a start of Nov 2005, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Capecitabine · Fluorouracil · Leucovorin